Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.972411
Abstract: Pyrotinib, a novel irreversible epidermal growth factor receptor dual tyrosine kinase inhibitor, is mainly (about 90%) eliminated through cytochrome P450 (CYP) 3A mediated metabolism in vivo. Meanwhile, genotype is a key factor affecting pyrotinib clearance… read more here.
Keywords: pyrotinib exposure; endogenous biomarker; model; pyrotinib ... See more keywords